Glycemia in newborns of hypertensive mothers according to maternal treatment.
OBJECTIVE
To evaluate the evolution of glycemic levels in newborns of hypertensive mothers according to maternal treatment.


METHODS
Prospective randomized study, including 93 newborns of mothers treated with isradipine (n = 39), atenolol (n = 40), or low sodium diet (control group - n=14). Glycemia was determined at birth (mother and newborn by the oxidase glucose method) and in the 1st, 3rd, 6th, 12th, and 24th hours after birth (newborn by a test strip method). The evolution of glycemia was analyzed in each group (Friedman test). The groups were compared regarding glycemia (Kruskall-Wallis test), and linear regression models were constructed for the analyses (independent variable = maternal glycemia; dependent variables = umbilical cord, 3rd, and 6th hour glycemia).


RESULTS
There were no statistically significant differences among the mean blood glucose levels of the 3 groups in any of the assessments. There was a correlation between maternal and umbilical cord blood glucose in the isradipine (r = 0.61; P <.05) and control (r = 0.84; P <.05) groups. Regarding glycemia levels of the mothers and newborns in the third and sixth hours postpartum, this correlation was present only in the control group (maternal x third hour: r = 0.65; P <.05; maternal x sixth hour: r = 0.68; P <.05). There were no correlations in the atenolol group. Hypoglycemia was detected in 51.3% of the isradipine group, 60% of the atenolol group, and 35.7% of the control group, and it was more frequent in the first hour postpartum in all groups.


CONCLUSIONS
The results suggest a similar effect of the 3 types of treatment upon newborn glycemia. The correlation analysis suggests that isradipine could have effects upon newborn glycemia only after birth (correlation only in umbilical cord blood), whereas atenolol could act earlier (there was no correlation at any moment). The results also point to the need for glycemic control from the first hour postpartum of newborns of hypertensive mothers whether they have or have not undergone treatment with antihypertensive drugs.
Darcie
Silvana
S
Department of Pediatrics, Hospital das Clínicas, Faculty of Medicine, University of São Paulo, São Paulo, SP, Brazil. sdarcie@uol.com.br
Leone
Cléa R
CR
Calil
Valdenise M L T
VM
Prescinotti
Elizete P
EP
Kahhale
Soubhi
S
Zugaib
Marcelo
M
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001034:Apgar Score; D001262:Atenolol / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis / Q000187:drug effects*; D004812:Epidemiologic Methods; D005260:Female; D005312:Fetal Blood / Q000737:chemistry; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D007231:Infant, Newborn; D017275:Isradipine / Q000627:therapeutic use*; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000097:blood / Q000188:drug therapy*
D000959:Antihypertensive Agents; D001786:Blood Glucose; D001262:Atenolol; D017275:Isradipine